The difference between these two is a piece of physics, and everything else follows from it. Accufit sticks adhesive electrodes to your skin and passes an electrical current between them. EmSculpt puts a coil over the area instead. A pulsed magnetic field induces that current inside the tissue, with nothing touching the muscle-stimulating circuit at all.
That single difference sets the ceiling on how hard each device can push. With electrodes, the current has to cross the skin, and the skin is where it hurts. The published Accufit pilot study says it outright: "Discomfort often limited the amount of current applied thereby limiting efficacy." A magnetic field skips the skin entirely. It passes through clothing and induces the current where the motor nerves are.
Accufit's aesthetic clearance is real, verifiable and recent. Mettler Electronics Corporation holds the clearances, under the trade name "accufit". K223802, decided 6 October 2023, is rehabilitation wording only. K233926, decided 21 March 2024, adds the body-contouring claims. Those are improvement of abdominal tone, strengthening of the abdominal muscles, development of a firmer abdomen, and improvement of muscle tone and firmness for strengthening muscles in arms, thighs and buttocks areas. The FDA letter for the second is addressed care of Lutronic's vice-president of global regulatory affairs, which is what ties the filings to the brand. A 510(k) clearance means FDA agreed the device is much the same as something already on the market. It is not a finding that it works.
The awkward fact that cuts against the clean physics story sits in EmSculpt's own FDA file. The first clearance in that family was granted against an electrode-based home-use stimulator. It states that "the current induced by the magnetic field is almost identical compared to the predicate device." So the case for magnetic stimulation was built on the currents being much like those of a contact device.
Accufit's evidence is smaller, but it includes something the electromagnetic literature mostly lacks. It includes an objective strength measurement.
Lutronic calls the technology Bioelectric Muscle Activation. It usually runs eight electrodes across several channels. You can see them on you.
A coil inside the applicator makes the field. Nothing is stuck to the skin, and the field passes through clothing.
Where you place the electrodes is where the current runs. So placement decides which muscle fires and how the contraction is shaped.
There is no skin interface in the stimulating circuit. The contractions are described as supramaximal, meaning stronger than your own effort produces.
The Accufit pilot study says so directly: "discomfort often limited the amount of current applied thereby limiting efficacy." That is the problem the device was built around.
The honest counterweight sits in FDA's own summary for the first clearance in this family. It compares the two approaches. It calls the induced currents almost identical to those of the electrode-based predicate, which was a home-use device.
K223802 (6 October 2023) covers six rehabilitation uses. They are relaxing muscle spasms, preventing disuse atrophy, raising local blood flow, muscle re-education, keeping or increasing range of motion, and calf stimulation after surgery to prevent blood clots. K233926 (21 March 2024) adds abdominal tone. It also adds muscle tone and firmness for arms, thighs and buttocks. Prescription use. The applicant on both is Mettler Electronics Corporation.
Fat reduction, circumference reduction and skin claims appear in none of the matching filings. BTL files under model numbers rather than trade names, and FDA does not publish a brand-to-clearance link. So matching those filings to the name "EmSculpt" is an inference from the device descriptions.
Calves are not included.
That mapping is inferred from the device descriptions, because FDA does not publish a brand-to-clearance link for BTL. The published evidence leans heavily to the abdomen. One critical review counted 378 patients studied for the abdomen, 156 for buttocks, 22 for arms and 15 for calves.
The pilot study describes "tingling and pressure with minimal discomfort." Electrodes have to be placed on bare skin, and they are visible during the session.
Delayed soreness like the day after hard exercise is the common after-effect. FDA summarised a manufacturer study of the radiofrequency-plus-electromagnetic version of this device. In it, 11 of 42 subjects reported muscle soreness after treatment.
A pilot in 29 people gave four 30-minute abdominal sessions. It checked them at 30 days by photo, weight, tape measure and ultrasound. Blinded photo grading agreed above 90%. Then 45 people had four 30-minute arm sessions twice weekly, measured on a dynamometer. Top biceps strength rose 7.5 lb (22.83%) by the last treatment, and 13.3 lb (34.13%) at 30 days after. Top triceps strength rose 10.0 lb (23.16%). Neither study carries a conflict-of-interest statement in its record. The device is Lutronic's.
A review of 14 electromagnetic body-contouring studies found mean muscle thickness up 2.2 mm and mean fat thickness down 5.5 mm. One of the 14 had a sham group. A separate review of 15 studies found that none reported patient weight change. Strength testing is largely missing from this research.
That is the protocol in both published studies.
BTL does not publish instructions for use, so there is no labelled schedule. The four-session figure traces to a study that gave eight abdominal treatments. It concluded that four delivered 86% of the improvement seen.
An electrode-based stimulator has to get current through the skin. Skin is a poor conductor, and it is full of sensory nerves. So as you turn the current up, the electrode site starts to sting long before the muscle underneath has been driven as hard as it could be. That is a hard ceiling. It is why electrode devices spread the current across many pads rather than pushing one hard.
A magnetic stimulator does not have that problem. The field is not blocked by skin, fat or clothing. The current appears where the field changes fastest inside the tissue. What you feel is the muscle contracting, not the delivery.
That is a real difference, and it explains the practical ones. Whether you undress. Whether anything is stuck to you. How many separate placements are needed to cover an area. And how the sensation is spread out.
Do not overstate it, though: FDA's summary for the first clearance in the EmSculpt family made a specific case. The current induced by the magnetic field was almost identical to that of a contact device meant for home use. The regulator's own document treats both as delivering much the same current to the target. The difference is in how much you can bear, not in a different kind of contraction.
The clearances whose device descriptions match EmSculpt carry abdominal, buttock and thigh wording from February 2017, arms from October 2018 and calves from July 2019. That mapping is inferred from the device descriptions, because FDA does not publish a brand-to-clearance link for BTL. Accufit's aesthetic wording dates from 21 March 2024, about six years later. It covers abdomen, arms, thighs and buttocks, with no calves. Before that, the same device was cleared only for rehabilitation uses. That is why the 2024 arm strength study describes it as cleared as a two-channel muscle stimulator rather than as a body-contouring device.
That does not make the newer clearance weaker. It does mean something for how you read older results. If you are reading Accufit results published before 2024, you are reading results generated on a device not yet cleared for the cosmetic use it is now sold for.
Lutronic also holds a clearance for a device called CoreLevee, decided 14 October 2022. That one is a magnetic stimulator of the EmSculpt type. Its cleared predicate is a BTL EmSculpt-family model. So the same company sells both an electrode device and a magnetic device. If a clinic offers you "the Lutronic muscle machine", ask which one. The mechanism, the sensation and the setup are all different.
Neither one removes fat. FDA's consumer guidance on electronic muscle stimulators states that "no EMS devices have been cleared at this time for weight loss, girth reduction, or for obtaining 'rock hard' abs." It also says that using these devices alone will not give you six-pack abs.
Disclose any pacemaker, implanted defibrillator, neurostimulator, drug pump, or metal implant near the treatment area: Both devices work by driving current through tissue, and both device types exclude implants.
Say if you have epilepsy or a seizure disorder, a bleeding disorder, a cancer in the area, recent surgery in the area, or a hernia in or near the abdomen: Neither BTL nor Lutronic publishes freely available patient-facing labelling. Allergan's published safety information for CoolTone, a magnetic muscle stimulator in the same FDA device class, names those as contraindications or cautions - a guide to how the class is labelled, not EmSculpt's or Accufit's own labelling.
If you have sensitive skin or an adhesive allergy, mention it before an electrode-based treatment: The pads are stuck to bare skin for half an hour.
Ask which area is being treated, and check it against the cleared wording: Accufit's aesthetic wording covers abdomen, arms, thighs and buttocks. EmSculpt's adds calves.
Fever or chills after treatment
Redness around a treated area that is visibly spreading hour by hour
Pus or discharge from treated skin
Any electric shock felt from the device, or a burn that blisters at an electrode site
These need care the same day.
Muscle soreness is bad enough to stop you moving normally, or lasts more than a few days
A red, itchy or raised patch appears exactly where an electrode pad sat and is not settling
A firm lump appears in a treated area and does not settle over a few weeks
Pain in a treated area increases after day three instead of settling
Numbness or altered sensation in a treated area is not improving